Free Trial

Cara Therapeutics Q2 2023 Earnings Report

Cara Therapeutics logo
$5.22 -0.14 (-2.61%)
As of 01/3/2025 05:39 PM Eastern

Cara Therapeutics EPS Results

Actual EPS
-$6.96
Consensus EPS
-$6.72
Beat/Miss
Missed by -$0.24
One Year Ago EPS
N/A

Cara Therapeutics Revenue Results

Actual Revenue
$6.93 million
Expected Revenue
$6.49 million
Beat/Miss
Beat by +$440.00 thousand
YoY Revenue Growth
N/A

Cara Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Cara Therapeutics Earnings Headlines

How this >10-cent coin is going to outperform Bitcoin
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…
Cara Therapeutics trading halted, news pending
See More Cara Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cara Therapeutics and other key companies, straight to your email.

About Cara Therapeutics

Cara Therapeutics (NASDAQ:CARA), a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

View Cara Therapeutics Profile

More Earnings Resources from MarketBeat